Am J Kidney Dis by Grubbs, Vanessa et al.
Americans’ Use of Dietary Supplements That Are Potentially 
Harmful in CKD
Vanessa Grubbs, MD, MPH1, Laura C. Plantinga, ScM2, Delphine S. Tuot, MD, MAS1, 
Elizabeth Hedgeman, MS, MPH3, Rajiv Saran, MD, MS3, Sharon Saydah, PhD4, Deborah 
Rolka, MS4, Neil R. Powe, MD, MPH, MBA2, and Centers for Disease Control and Prevention 
CKD Surveillance Team*
1University of California, San Francisco General Hospital, Division of Nephrology
2University of California, San Francisco General Hospital, Department of Medicine
3University of Michigan, Department of Internal Medicine, Division of Nephrology
4Division of Diabetes Translation, Centers for Disease Control and Prevention
Abstract
Background—The prevalence in the United States of dietary supplement use that may be 
harmful to those with chronic kidney disease (CKD) is unknown. We sought to characterize 
potentially harmful supplement use by individual CKD status.
Study Design—Cross-sectional national survey (National Health and Nutrition Examination 
Survey, 1999-2008)
Setting & Participants—Community-based survey of 21,169 non-pregnant, non-
institutionalized U.S. civilian adults (≥20 years)
Predictor—CKD status (no CKD, at risk for CKD [presence of diabetes, hypertension and/or 
cardiovascular disease], stage 1/2 [albuminuria only (albumin-creatinine ratio ≥30 mg/g)], or stage 
3/4 [estimated glomerular filtration rate of 15-59 ml/min/1.73 m2]).
Outcome—Self-reported use of dietary supplements containing any of 37 herbs the National 
Kidney Foundation identified as potentially harmful in the setting of CKD.
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Measurements—Albuminuria and estimated glomerular filtration rate assessed from urine and 
blood samples; demographics and comorbid conditions assessed by standardized questionnaire.
Results—An estimated 8.0% of U.S. adults reported potentially harmful supplement use within 
the last 30 days. Lower crude estimated prevalence of potentially harmful supplement use was 
associated with higher CKD severity (no CKD, 8.5%; at risk, 8.0%; stage 1/2, 6.1%; and stage 3/4, 
6.2%; p<0.001). However, after adjustment for confounders, those with or at risk for CKD were as 
likely to use a potentially harmful supplement as those without CKD: at-risk OR, 0.93 (95% CI, 
0.79 -1.09); stage 1/2 OR, 0.83 (95% CI, 0.64 -1.08); stage 3/4 OR, 0.87 (95% CI, 0.63 -1.18); all 
vs. no CKD.
Limitations—Herb content was not available and the list of potentially harmful supplements 
examined is unlikely to be exhaustive.
Conclusions—The use of dietary supplements potentially harmful to people with CKD is 
common, regardless of CKD status. Healthcare providers should discuss the use and potential risks 
of supplements with patients with and at risk for CKD.
Chronic kidney disease (CKD) in the United States is common, affecting an estimated 14% 
of the general adult population who are aged 20 years or older.1 Currently, over 600,000 
Americans have progressed to chronic kidney failure requiring renal replacement therapy, a 
condition that is associated with excess morbidity and mortality.2 Therefore, it is critically 
important to identify possible risks for and measures to decrease CKD progression.
Avoidance of substances that may be harmful to the kidney is one important method of 
reducing CKD progression. Although many herbs commonly found in dietary supplements 
can cause acute kidney injury and other forms of kidney injury,3 they are not subject to 
rigorous governmental standards for content or safety for the general population4 or for 
individuals with CKD, in whom the consequences could be particularly deleterious. Because 
roughly half of US adults report using dietary supplements,5,6 these products may be an 
important source of adverse renal effects that are under-recognized by both patients and 
providers.
To our knowledge, only a few small studies7-9 have described the use of dietary supplements 
among patients with CKD, or more specifically end-stage renal disease, and none have 
focused on supplements that may be harmful in the setting of kidney disease. In a nationally 
representative sample, we sought to characterize the extent of dietary supplement use that 
may have harmful consequences for persons with or at risk for CKD.
METHODS
Study Population
The study population was drawn from the National Health and Nutrition Examination 
Survey (NHANES).10 NHANES is a well-established representative survey of non-
institutionalized civilian residents in the United States conducted by the National Center for 
Health Statistics of the U.S. Centers for Disease Control and Prevention. It consists of a 
standardized in-home interview, followed by a physical examination and blood and urine 
collection at a mobile examination center. All participants provide written informed consent. 
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The protocol was approved by the National Center for Health Statistics Research Ethics 
Review Board. We included 21,169 non-pregnant, adult participants from NHANES 
1999-2008 who met our study criteria. From a denominator of 24,693 adults aged ≥20 years, 
we excluded 9 with missing dietary supplement use data; an additional 2,262 with missing 
kidney function data; and finally 1,253 more with estimated glomerular filtration rate 
(eGFR) below 15 ml/min/1.73 m2. We excluded those with very low eGFR because our goal 
was to focus on individuals who would most benefit from identifying behaviors that may 
predispose to nephrotoxicity or CKD progression. After these exclusions, there were no 
pregnant participants remaining.
Measurements
Serum creatinine concentration was measured by the modified kinetic method of Jaffe using 
different analyzers in different survey years. Creatinine levels were calibrated as specified in 
NHANES documentation.11,12 Random spot urine samples were obtained; and urine 
albumin was measured using solid-phase fluorescence immunoassay and urine creatinine 
was measured using the modified Jaffe kinetic method in the same laboratory11 on frozen 
samples.
Definitions
Participants who responded “yes” to the question “Have you used or taken any vitamins, 
minerals, or other dietary supplements in the past month?” were asked to provide bottles for 
the individual supplements they took. Each provided supplement was classified as either 
potentially harmful in the setting of CKD or “other.” A supplement was considered 
potentially harmful if it contained at least 1 of 37 distinct herbs identified from literature 
review and expert opinion by the Council on Renal Nutrition for the National Kidney 
Foundation (NKF).13 We reviewed supplement ingredients using the variable dsdingr 
(ingredient name) in the Dietary Supplement Database-File 4, to determine the presence of 
any of the 37 potentially toxic herbs. For ingredients noted as “proprietary blends,” we 
located the actual product label to identify ingredients. In the event the product label could 
not be found, the variable dsdbcnam (blend component name, also in File 4) was queried. 
Participants were classified as taking any potentially harmful supplement, taking only 
“other” supplements, or taking no supplements.
We defined CKD status as no CKD; at risk only, by presence of strong CKD risk factors 
(including diabetes, hypertension or cardiovascular disease); stage 1/2 CKD, as albuminuria 
only (urine albumin-creatinine ratio, ≥30 mg/g) with eGFR ≥60 ml/min/1.73 m2; or stage 
3/4 CKD, as eGFR 15-59 ml/min/1.73 m2, regardless of albuminuria. Estimated GFR was 
calculated using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: GFR 
= 141 × min(Scr/κ,1)α × max(Scr/κ,1)−1.209 × 0.993age × 1.018 [if female] × 1.159 [if 
black], where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is 
−0.329 for females and −0.411 for males, min indicates the minimum of Scr/κ or 1, and max 
indicates the maximum of Scr/κ or 1.14
We defined diabetes by participant self-report. Hypertension was defined by self-report or 
an average of second and third blood pressure readings ≥140 mmHg systolic or ≥90 mmHg 
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diastolic. Cardiovascular disease included self-report of coronary artery disease, stroke, 
heart attack, congestive heart failure, or angina.
We categorized age into three groups (20-44, 45-64, and ≥65 years) and used NHANES 
categories of self-reported race/ethnicity as non-Hispanic white, non-Hispanic black, 
Mexican-American, or other. Educational attainment was categorized as more than high 
school, high school or high school equivalent, and less than high school. We categorized 
income using the U.S. Census Bureau’s poverty index ratio (the ratio of family income to 
federal poverty level, where ≤1.00 is considered below the poverty level) into three groups 
(poverty index ratio ≤1.00, >1-<3, or ≥3). We included self-reported arthritis and cancer as 
co-morbid conditions ascertained uniformly in our study population that may prompt 
individuals to take dietary supplements as a means of prevention or treatment. 15
Tobacco use (no/past versus ongoing) was defined by significant lifetime use of cigarettes 
(≥100), snuff (≥20 times), and/or chewing tobacco (≥20 times). Current alcohol use was 
categorized as none/moderate versus heavy (>7 drinks/wk for women or >14 drinks/wk for 
men). We defined healthcare utilization as the number of healthcare visits within the last 12 
months as a continuous variable to examine the effect of encounters with healthcare 
providers on supplement use.
Statistical Analysis
We calculated the proportion of all reported supplements containing at least one NKF-
identified herb, and the proportion of potentially harmful supplements containing each 
specific NKF-identified herb. We used ordinal logistic regression to test whether supplement 
use varied by survey year. Among U.S. adults aged 20 years or older, we estimated the 
prevalent use of potentially harmful or only other supplements overall and by CKD status 
within groups defined by demographic characteristics, comorbid conditions, health-related 
behaviors, and healthcare visits. Among the subpopulation of U.S. adults who took any 
supplement, we used chi-square analysis to test whether potentially harmful supplement use 
varied by CKD status within each of these groups. We estimated the frequency and duration 
of any potentially harmful supplement use and used chi-square analysis to test whether these 
estimates were associated with CKD status. Finally, we used multivariable logistic 
regression to assess the presence, direction, strength, and independence of the association 
between taking a potentially harmful supplement and CKD status, among those taking any 
supplement. We added covariates to the model sequentially to examine their incremental 
effects on the likelihood of taking a potentially harmful supplement. We performed 
sensitivity analyses with CKD defined by GFR estimated according to the isotope-dilution 
mass spectrometry–traceable 4-variable Modification of Diet in Renal Disease (MDRD) 
Study equation.16 All analyses used recommended sampling weights11 and were performed 
using the “SVY” commands in STATA v. 12.0 (StataCorp LP, College Station, TX) to 
account for the study design.
RESULTS
Participants in our study reported use of 5,280 distinct supplements, of which 14.3% (n=757 
unique supplements) were potentially harmful. Of the 37 NKF-identified herbs, 18 were 
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found among supplement ingredients (Table S1, available as online supplementary 
material). Potential adverse renal effects of herbs found in reported dietary supplements are 
shown in Table 1.17 Ginseng was the most commonly found NKF-identified herb, contained 
in an estimated 36.5% of potentially harmful dietary supplements, followed by ginger 
(23.6%), alfalfa (19.6%), capsicum (14.9%), licorice (14.8%), dandelion (10.3%), aloe 
(9.3%), ma huang (7.4%), nettle (7.4%), horsetail (6.0%), yohimbe (2.6%), rhubarb (2.3%), 
cascara (2.0%), noni (1.0%), senna (1.0%); and broom, wormwood, bayberry, and buckthorn 
(<1.0% each). The most commonly (>1%) reported potentially harmful supplements, 
including several multivitamin formulations, and their NKF-identified herbal ingredients are 
listed in Table 2.
Among U.S. adults aged 20 years or older, supplement use did not vary across survey years 
(p=0.3 by chi-square). An estimated 8.0% used a potentially harmful supplement(s) and an 
additional 44.5% used other supplement(s) (Table 3). These estimates were similar among 
participants who were excluded due to lack of kidney function data (p=0.8 by chi-square). 
The overall prevalence of potentially harmful supplement use was lower with higher CKD 
status and age, but that of other supplement use was higher with these characteristics. This 
pattern was similar by CKD status. Supplement use (potentially harmful and other) was 
most common among non-Hispanic whites, both overall and within each CKD status 
stratum. Overall, the prevalence of potentially harmful and other supplement use was higher 
among persons with higher income, educational attainment, and number of healthcare visits. 
A similar pattern was found in analyses within each CKD status stratum.
The vast majority of participants taking a potentially harmful supplement had done so nearly 
every day within the past month (Figure 1) and the frequency of use was not significantly 
different by CKD status (as defined by CKD-EPI equation, p=0.3; or by MDRD Study 
equation, p=0.1). Nearly one-third of study participants taking potentially harmful 
supplements reported doing so for more than 3 years (Figure 2), which was increasingly 
common with greater CKD severity (as defined by CKD-EPI equation: 24.8% for no CKD, 
32.9% for at risk, 40.1% for stage 1/2, and 50.5% for stage 3/4 [p=0.002]; or by MDRD 
Study equation: 24.7% for no CKD, 32.9% for at risk, 40.8% for stage 1/2, and 45.1% for 
stage 3/4 [p=0.008]).
Among supplement users (n=10,224), the unadjusted model indicated that persons with or at 
risk for CKD had a lower likelihood of taking a potentially harmful supplement as compared 
to those without CKD (Table 4). This finding was attenuated after adjustment for age. 
Additional adjustment for gender, race/ethnicity, poverty index ratio, educational attainment, 
co-morbid conditions, tobacco and alcohol use, or number of healthcare visits did not 
significantly change these findings. Of note, the number of healthcare visits was not a 
significant independent predictor of taking a potentially harmful supplement. Results were 
similar when CKD status was defined by the MDRD Study equation (Tables S2-S3).
DISCUSSION
Dietary supplements are widely used in the United States, despite their potential for harmful 
effects.18 Individuals with or at risk for CKD may be particularly vulnerable to harmful 
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effects of supplement use through direct nephrotoxicity and other renal complications, as 
well as decreased clearance of substances, resulting in adverse product accumulation. To our 
knowledge, our study is the first to describe the use of dietary supplements potentially 
harmful in persons with and at risk for CKD in a nationally representative sample. Similar to 
the findings in other studies,5,6 we found that more than half of U.S. adults (age ≥20 years) 
reported taking any supplement within the 30 days prior to the survey. We show that 
roughly 1 in 12 U.S. adults is taking at least one supplement that is potentially harmful in 
persons with kidney disease and that those with or at risk for CKD have a similar likelihood 
of taking such supplements when compared to those without CKD, after accounting for 
important confounders. Certainly, our findings that potentially harmful supplements are 
frequently marketed under seemingly benign product names (such as multivitamins) and by 
trusted manufacturers, as well as that most individuals report taking them nearly every day 
and for prolonged periods of time, underscore the scope of this issue.
The lack of variability by CKD status in taking potentially harmful supplements may in part 
be due to unawareness of CKD. An estimated 80%-90% of individuals with substantially 
decreased kidney function are unaware of their CKD.19,20 Further, most individuals with 
CKD may be unaware they are at increased risk of harm, given that consumers often assume 
“natural” products are safe and beneficial to health.21 Unawareness regarding potential harm 
of supplements may also be attributed to the lack of rigorous pre-marketing regulation and 
safety testing. With the passage of the Dietary Supplement Health and Education Act in 
1994 (which classified supplements as a subcategory of food, rather than a drug) 22 
manufacturers were permitted to market supplement products directly to consumers without 
submitting proof of safety or efficacy to the U.S. Food and Drug Administration. 
Consequently, marketing of these products often includes information that is inaccurate and 
possibly deceptive.23-25 Furthermore, products are often not available in reliable or 
consistent potencies and dosages, making research on safety or efficacy extremely 
difficult.26
While aristolochic acid nephropathy, a rapidly progressive interstitial fibrosis of the kidneys 
frequently leading to end-stage renal disease and urothelial carcinomas, is one of the most 
dramatic and highly cited examples of herb-induced nephrotoxicity,27,28 the ingestion of 
more common herbs contained in supplements may be an underappreciated source of 
nephrotoxicity or other adverse effects of particular concern in those at risk for or with 
advanced CKD. For example, dietary supplements containing herbs that increase blood 
pressure or worsen glycemic control may indirectly lead to or worsen existing CKD. Dietary 
supplements containing herbs that induce hypoglycemia or hyperkalemia may be of 
particular risk for those with advanced CKD. Older individuals and those with concomitant 
medication use may be particularly vulnerable.3 Similarly, dietary supplements containing 
herbs that lead to diarrhea and vomiting may cause decreased kidney perfusion that results 
in acute kidney injury, an established CKD risk factor.29,30 Since patients may be less likely 
to attribute harmful effects to dietary supplements,21 there may be delays in diagnosing the 
etiology of such complications.
Interestingly, we found that the prevalence of both potentially harmful and other supplement 
use was higher with higher number of healthcare visits. We expected that those with more 
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healthcare visits would have a lower prevalence of potentially harmful supplement use 
because of more opportunities for healthcare providers to assess and advise against 
potentially harmful ingestions. This contradictory finding may be explained by people with 
chronic conditions having more frequent healthcare encounters and higher likelihood of 
complementary and alternative medicine use than those without a chronic condition15 but 
may also be a reflection of provider recommendations supporting the patient’s use of 
generally accepted supplements (e.g., vitamin D and calcium) but lack of awareness 
regarding the patient’s use of potentially harmful supplements or CKD status. Provider 
unawareness may be due to a failure to ascertain whether the patient is taking other 
supplements, coupled with provider unawareness of dietary supplement safety31 and 
purposeful patient non-disclosure. This assertion is supported by our finding that the number 
of healthcare visits did not affect the likelihood of taking a potentially harmful supplement 
but was an independent predictor for taking other dietary supplements (data not shown). In a 
national health survey of supplement users, only 33% of individuals---and 51% of 
individuals with chronic conditions---reported disclosing this use to their primary healthcare 
provider,32 possibly due to skepticism of provider knowledge and attitude toward 
supplements.21
Prior research has shown that those with higher educational attainment and income are more 
likely to use supplements, possibly because these individuals are more knowledgeable 
regarding purported supplement indications and have greater disposable income for such 
purchases than less well-educated or affluent Americans.33 In our study, the finding that 
prevalence of supplement use potentially harmful in kidney disease was also higher among 
adults with higher educational attainment and income may suggest a general lack of 
awareness of the risk these supplements may impose.
We recognize limitations of our study. First, because the NKF website is a prominent 
resource for public health education about kidney health, we chose to investigate only the 
herbs listed on the website as it may have served as a possible deterrent for potentially 
harmful supplement use for those with CKD. However, this list is unlikely to be exhaustive. 
For example, the list did not include acai berry, an herb touted for weight loss but has 
COX-1 and COX-2 inhibitory action34 like certain non-steroidal anti-inflammatory drugs, 
which are associated with acute kidney injury in the general population35 and with disease 
progression among those with CKD.36 Further, the NHANES question to ascertain 
supplement use does not specifically include teas, which may be important but under-
recognized sources of potentially harmful herbs. Therefore, our finding that roughly 14% of 
reported supplements are potentially harmful in the setting of CKD is likely conservative. A 
more comprehensive list of herbs may have resulted in even higher estimates. On the other 
hand, of herbs included on the NKF list and reported among our study population, broom 
was the only herb for which we found no associated literature for adverse renal effects. 
Therefore, our estimate of prevalence is unlikely to be an underestimation of prevalent use 
of potentially harmful supplements.
Similarly, we acknowledge that some herbs included in the NKF list may have potential 
benefits. Senna, for example, is widely prescribed for constipation and a recent uncontrolled 
pilot trial found wormwood significantly reduced proteinuria in 10 patients with IgA 
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nephropathy.37 However given the lack of consistency between products,26,38 the lack of 
rigorous safety or efficacy testing, and tendency for patients to believe people are rarely or 
never harmed by supplements,21 it is important to raise awareness of potential harm.
Moreover, we did not examine dosages of supplements taken and, therefore, cannot 
conclude that individuals taking potentially harmful supplements are taking enough to do 
significant harm. Given the wide variety of documented discrepancies in product label 
claims and actual content in addition to possible undisclosed contaminations,38,39 true 
quantitation and comparison of dosages would be impossible without direct product 
analysis. Regardless, it is important to note that a substantial proportion of our study 
population reported taking supplements over many years, possibly placing themselves at risk 
of cumulative effects. Consistent with this possibility, we found that individuals with CKD 
were more likely to report long-term supplement use than those with preserved kidney 
function. While we are unable to determine causality due to study design, this association 
highlights the need for further examination of the longitudinal relationship between 
supplement use and kidney function.
In conclusion, the use of dietary supplements potentially harmful in the setting of CKD is 
common regardless of CKD status, even after accounting for confounders. Further study of a 
more comprehensive list of potentially harmful herbs and repeated measures to determine 
the actual risk to kidney function or other organ systems resulting from supplement use is 
needed. Nevertheless, this study supports the recommendation that providers vigilantly ask 
patients about all ingestions and appropriately advise patients about potential risks within 
the context of their CKD status.
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Table 1




Alfalfa Triggers lupus - -
Aloe Albuminuria, acute or progressive
kidney injury
- Hypovolemia
Bayberry -- - Hypovolemia
Broom - - -
Buckthorn Albuminuria - Hypovolemia
Capsicum - - Hypovolemia
Cascara Albuminuria - Hypovolemia
Dandelion - - Hypovolemia
Ginger - - Hypoglycemia
Ginseng - - Hypoglycemia
Horsetail - - Hypoglycemia
Licorice - High BP -
Ma huang - Hyperglycemia, high BP,
kidney stones
Hypovolemia
Nettle Acute or progressive kidney injury Hyperglycemia -
Noni - - Hyperkalemia
Pokeroot - - Hypovolemia
Rhubarb - - Hypovolemia
Senna Acute or progressive kidney injury - Hypovolemia
Wormwood Acute or progressive kidney injury,
rhabdomyolysis
- Hypovolemia
Yohimbe Acute or progressive kidney injury,
triggers lupus
- -
Note: hypovolemia due to diarrhea and/or vomiting.
BP, blood pressure; NKF, National Kidney Foundation; CKD, chronic kidney disease
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Table 2





Centrum Advanced Formula Carb Assist Complete Multivitamin/
Multimineral From A to Zinc
3.4 ginseng
GNC Men’s Timed Release Senior Formula 1.7 ginseng, nettle
Centrum Performance Complete Multivitamin Specially Formulated With
Ginseng, Ginkgo, and Higher Levels Of 5 Essential B
1.6 ginseng
One Source Complete Women’s With Ester-C Calcium 500mg Cranberry
EGCG (Green Tea Extract) Multivitamin Mineral & Herb
1.6 ginseng
GNC Men’s Ultra Saw Palmetto Formula 1.4 ginseng
One Source Complete Women’s Multivitamin/ Multimineral/ Herbs with
EGCG Green Tea Extract 27mg & Cranberry 50mg
1.4 ginseng
Member’s Mark Advanced Multi Performance Multivitamin for Adults 1.3 ginseng
Member’s Mark Advanced Multi with Herbs 1.1 ginseng
Metabolic Cleansing System 343 Advocare 1.1 aloe
One Source Pure Performance The Advanced Formula Multivitamin
Multimineral Herbs Formulated for Active Adults Complete
1.1 ginseng
Note: n=1,421, , among US adults aged >20 years taking potentially harmful supplement, NHANES 19992008.
NHANES, National Health and Nutrition Examination Survey; NKF, National Kidney Foundation
GNC = General Nutrition Centers
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